STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

Summary

Oak Hill Bio, backed by RA Capital and other investors, is entering the rare disease space to develop an Angelman syndrome treatment, competing with established players Ultragenyx and Ionis.